News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Genomic Test Spares Patients Chemotherapy With No Adverse Effect on Survival, Netherlands Cancer Institute (NCI) Study



3/22/2012 7:44:31 AM

Testing a breast cancer tumour for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, according to the results of a study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Thursday). Dr. Sabine Linn, an Associate Professor of Medical Oncology at The Netherlands Cancer Institute, Amsterdam, The Netherlands, will say that this is the first study where such a test has been incorporated in decision-making about adjuvant systemic therapy, and that the results are promising.

Read at EurekAlert!
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES